Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
PB Ratio: Premium Valuation
Trending higher, above historical average, strong compound growth.
Left:
||||
Price-to-book ratio
Latest
6.23
↑ 165% above average
Average (9y)
2.36
Historical baseline
Range
High:6.23
Low:0.37
CAGR
+36.9%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | 6.23 | +59.3% |
| 2023 | 3.91 | +52.3% |
| 2022 | 2.57 | +5.4% |
| 2021 | 2.44 | -7.6% |
| 2020 | 2.64 | +21.0% |
| 2019 | 2.18 | +106.3% |
| 2018 | 1.06 | -30.1% |
| 2017 | 1.51 | +136.4% |
| 2016 | 0.64 | +73.4% |
| 2015 | 0.37 | - |